Post Menopausal Osteoporosis - Pipeline Review, H1 2018

  • ID: 4521338
  • Report
  • 87 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Amgen Inc
  • Enteris BioPharma Inc
  • GL Pharm Tech Corp
  • Intas Pharmaceuticals Ltd
  • Ipsen SA
  • Lupin Ltd
  • MORE
Post Menopausal Osteoporosis - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Post Menopausal Osteoporosis - Pipeline Review, H1 2018, provides an overview of the Post Menopausal Osteoporosis (Metabolic Disorders) pipeline landscape.

Postmenopausal osteoporosis is the most common form of osteoporosis. It affects many women after menopause. Symptoms include back pain, loss of height, or spinal deformities such as stooped posture. Risk factors include age, gender, family history, bone structure and body weight. Treatment includes hormone replacement therapy (HRT) and vitamin D analogues.

Report Highlights:

This latest pipeline guide Post Menopausal Osteoporosis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Post Menopausal Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post Menopausal Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Post Menopausal Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase I and Preclinical stages are 5, 2, 3 and 6 respectively.

Post Menopausal Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Post Menopausal Osteoporosis (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Post Menopausal Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Post Menopausal Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Post Menopausal Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Post Menopausal Osteoporosis (Metabolic Disorders)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Post Menopausal Osteoporosis (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Post Menopausal Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amgen Inc
  • Enteris BioPharma Inc
  • GL Pharm Tech Corp
  • Intas Pharmaceuticals Ltd
  • Ipsen SA
  • Lupin Ltd
  • MORE
Introduction

Report Coverage

Post Menopausal Osteoporosis - Overview

Post Menopausal Osteoporosis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Post Menopausal Osteoporosis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Post Menopausal Osteoporosis - Companies Involved in Therapeutics Development

Amgen Inc

Enteris BioPharma Inc

GL Pharm Tech Corp

Intas Pharmaceuticals Ltd

Ipsen SA

Lupin Ltd

Luye Pharma Group Ltd

NIBEC

Oncobiologics Inc

Paras Biopharmaceuticals Finland Oy

Uni-Bio Science Group Ltd

Post Menopausal Osteoporosis - Drug Profiles

(cholecalciferol + risedronate sodium) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

abaloparatide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

calcitonin DR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

denosumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

denosumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

denosumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

denosumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

denosumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

denosumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

denosumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Chelate Iron for Bone Degeneration, Postmenopausal Osteoporosis and Thalassemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HOB-078 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

romosozumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide for Obesity and Post Menopausal Osteoporosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

teriparatide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

teriparatide biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Post Menopausal Osteoporosis - Dormant Projects

Post Menopausal Osteoporosis - Discontinued Products

Post Menopausal Osteoporosis - Product Development Milestones

Featured News & Press Releases

Mar 22, 2018: Radius Health Provides Update on CHMP Opinion for Abaloparatide-SC

Mar 12, 2018: Radius Health to Present at ENDO 2018 Including Results of the ACTIVExtend BMD Responder Analysis for TYMLOS (abaloparatide) Injection

Jan 07, 2018: European Medicines Agency Accepts Filing For EVENITY

Dec 15, 2017: Radius Health Announces that the Committee for Medicinal Products for Human Use (CHMP) Will Issue a Third Day-180 List of Outstanding Issues in its Regulatory Review of Abaloparatide-SC, a Bone Building Agent for the Treatment of Osteoporosis in Postmenopausal Women at Increased Risk of Fracture

Nov 06, 2017: UCB to Present Data On Investigational Drug Romosozumab At 2017 ACR/ARHP Annual Meeting

Oct 13, 2017: Radius Health to Present First Health Economics Data on TYMLOS (abaloparatide) Injection at the Academy of Managed Care Pharmacy Nexus 2

Sep 11, 2017: EVENITY (romosozumab) ARCH Study Results Published In The New England Journal Of Medicine

Sep 10, 2017: Radius Health Presents Positive Data for TYMLOS (abaloparatide) Injection from the ACTIVExtend Trial at ASBMR 2017 Annual Meeting

Sep 08, 2017: Amgen Highlights Prolia (Denosumab) Research At The American Society For Bone And Mineral Research Annual Meeting

Sep 08, 2017: UCB highlights latest EVENITY research at the American Society for Bone and Mineral Research Annual Meeting

Sep 01, 2017: Radius Health to Present Eight Abstracts at the American Society of Bone and Mineral Research (ASBMR) 2017 Annual Meeting Including Results of the ACTIVE and ACTIVExtend Trials for TYMLOS (abaloparatide) Injection

Jul 21, 2017: Radius Health Announces that the CHMP Has Issued a Second Day-180 List of Outstanding Issues in its Regulatory Review of Eladynos (Abaloparatide-SC), a Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture

Jul 16, 2017: Amgen And UCB Provide Update On Regulatory Status Of EVENITY (romosozumab) In The US

Jun 14, 2017: New class drug significantly reduces spine fracture risk in postmenopausal women with osteoporosis

May 24, 2017: Radius Announces Positive Top-Line Results from Completed ACTIVExtend Study for TYMLOS in Postmenopausal Women with Osteoporosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Post Menopausal Osteoporosis, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Post Menopausal Osteoporosis - Pipeline by Amgen Inc, H1 2018

Post Menopausal Osteoporosis - Pipeline by Enteris BioPharma Inc, H1 2018

Post Menopausal Osteoporosis - Pipeline by GL Pharm Tech Corp, H1 2018

Post Menopausal Osteoporosis - Pipeline by Intas Pharmaceuticals Ltd, H1 2018

Post Menopausal Osteoporosis - Pipeline by Ipsen SA, H1 2018

Post Menopausal Osteoporosis - Pipeline by Lupin Ltd, H1 2018

Post Menopausal Osteoporosis - Pipeline by Luye Pharma Group Ltd, H1 2018

Post Menopausal Osteoporosis - Pipeline by NIBEC, H1 2018

Post Menopausal Osteoporosis - Pipeline by Oncobiologics Inc, H1 2018

Post Menopausal Osteoporosis - Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2018

Post Menopausal Osteoporosis - Pipeline by Uni-Bio Science Group Ltd, H1 2018

Post Menopausal Osteoporosis - Dormant Projects, H1 2018

Post Menopausal Osteoporosis - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Post Menopausal Osteoporosis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Amgen Inc
  • Enteris BioPharma Inc
  • GL Pharm Tech Corp
  • Intas Pharmaceuticals Ltd
  • Ipsen SA
  • Lupin Ltd
  • Luye Pharma Group Ltd
  • NIBEC
  • Oncobiologics Inc
  • Paras Biopharmaceuticals Finland Oy
  • Uni-Bio Science Group Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll